<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127384</url>
  </required_header>
  <id_info>
    <org_study_id>05DF1605</org_study_id>
    <nct_id>NCT03127384</nct_id>
  </id_info>
  <brief_title>Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars</brief_title>
  <official_title>A Randomised, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate performance and safety of Restylane Lidocaine for
      treatment of depressed facial acne scars
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall scar severity, assessed by blinded evaluator</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GAIS, assessed by subject, treating investigator and blinded evaluator</measure>
    <time_frame>1-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety by assessement of adverse events throughout the study</measure>
    <time_frame>0-13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>No-treatment control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection Restylane Lidocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Lidocaine</intervention_name>
    <description>Hyaluronic acid based filler</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No-treatment control</intervention_name>
    <description>No-treatment control</description>
    <arm_group_label>No-treatment control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intent to undergo treatment of depressed acne scars

          -  Presence of 5-20 scars with a diameter of up to approximately 4 mm within the
             treatment area

          -  Similar type, size and number of scars on both cheeks

          -  Men or non-pregnant, non-breast feeding women

          -  Fitzpatrick skin type I-IV

          -  Signed and dated informed consent to participate in the study

        Exclusion Criteria:

          -  Presence of more than 3 scars per cheek (within the treatment area) of the following
             types: icepick scars or atrophic acne scars with a diameter of &gt; 4 mm.

          -  Active acne with inflammatory component

          -  Use of per oral or topical (facial) substances containing retinoids, bensoyl peroxide,
             alpha-hydroxy acid at concentrations above 10%, beta-hydroxy acid at a concentration
             above 2%, or antibiotic treatment for active acne within 4 months before treatment

          -  Use of isotretinoin within 6 months before treatment

          -  Post-surgical scars in the treatment area

          -  Previous tissue augmenting therapy or contouring with permanent filler or
             fat-injection in the treatment area

          -  Previous tissue augmenting therapy, contouring or revitalisation treatment with
             Calcium Hydroxyapatite (CaHa), or Poly L-Lactic Acid (PLLA), in the treatment area
             within 24 months before treatment

          -  Previous tissue augmenting therapy, contouring or revitalisation treatment with
             non-permanent filler such as HA or collagen in the treatment area within 12 months
             before treatment

          -  Previous tissue revitalisation treatment with neurotoxin, laser or light, mesotherapy,
             chemical peeling or dermabrasion in the treatment area within 6 months before
             treatment

          -  Previous surgery including aesthetic facial surgical therapy, liposuction, or tattoo
             in the treatment area

          -  Any medical condition that, in the opinion of the treating Investigator, would make
             the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease
             that may interfere with the outcome of the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Q-Med AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

